Endogenous Granulocyte Macrophage Colony Stimulating Factor (GMCSF) is released in rheumatoid arthritis patients, who are largely protected from Alzheimer’s disease (AD). Introducing exogenous GMCSF into an AD mouse model reduced amyloid deposition by 55% and restored normal cognition. No published studies have examined exogenous GMCSF and cognitive functioning in humans. Amyloid reduction could result from induced phagocytosis by activated microglia/infiltrating macrophages and neutrophils with macrophages having greater phagocytic ability by induction of MMP-9 from infiltrating macrophages/neutrophils by reduced deposition, or by a combination of these mechanisms. Amyloid reduction could result from induced phagocytosis by activated microglia/infiltrating macrophages and neutrophils with macrophages having greater phagocytic ability by induction of MMP-9 from infiltrating macrophages/neutrophils by reduced deposition, or by a combination of these mechanisms.
Heather SL Jim, Granulocyte Macrophage Colony Stimulating Factor Treatment is
Associated with Improved Cognition in Cancer Patients
Last date updated on June, 2014
